MPP extends license for Atazanavir treatment for HIV to Ukraine
Google+
Facebook
Vkontakte
Odnoklassniki
The Medicines Patent Pool (MPP) has extended the license for Atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children, to Ukraine, the All-Ukrainian Network of People Living with HIV/AIDS (PLWH) has reported on its website."Six factories can supply the generic version of Atazanavir in the framework of this license. Thus, it is possible to predict a high competition for this drug that will lead to a sufficiently competitive price for Ukraine," the press service said, citing Policy and Advocacy Director of the All-Ukrainian Network of PLWH Serhiy Dmitriyev.
The agreement for the distribution and production of Atazanavir was reached with the pharmaceutical company Bristol-Myers Squibb.
Compared with the main alternative drug (lopinavir), ATV has certain advantages, such as a smaller number of side effects, being taken once a day, and easier manufacturing, which leads to lower prices.
In total, the license is valid in 122 middle- and low-income countries.
See also:
The Medicines Patent Pool (MPP) has extended the license for Atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children, to Ukraine, the All-Ukrainian Network of People Living with HIV/AIDS (PLWH) has reported on its website.
